Compound Detail
CHEMBL3402762
TEPOTINIB 💊 Approved Drug
Enter ChEMBL ID:
Free Research Context
This compound will appear in recent viewed items on the research home for this browser.
Research home
View demo workspace
💊 Approved Drug
CN1CCC(COc2cnc(-c3cccc(Cn4nc(-c5cccc(C#N)c5)ccc4=O)c3)nc2)CC1
Basic Information
| ChEMBL ID | CHEMBL3402762 |
| Name | TEPOTINIB |
| Phase | Approved |
| Structure Type | MOL |
| InChI Key | AHYMHWXQRWRBKT-UHFFFAOYSA-N |
| Therapeutic | ✓ Yes |
9
Targets
26
Activities
2
Assay Types
23
PK Parameters
20
Publications
7
Known Names
8
Indications
1
Mechanisms
Molecular Properties
492.6
MW (Da)
4.01
ALogP
8
HBA
0
HBD
96.9
PSA (Ų)
0.38
QED
0
Ro5 Violations
7
Rot. Bonds
Drug Information
| Molecule Type | Small molecule |
| First Approval | 2020 |
| Availability | Prescription |
| Chirality | Achiral |
Mechanism of Action
| Mechanism | Action Type | Target | Direct | Efficacy |
|---|---|---|---|---|
| Hepatocyte growth factor receptor inhibitor | INHIBITOR | Hepatocyte growth factor receptor | ✓ | ✓ |
Indications
Neoplasms Neoplasms Adenocarcinoma of Lung Carcinoma, Non-Small-Cell Lung Colorectal Neoplasms Brain Neoplasms Carcinoma, Hepatocellular Liver Diseases
ATC Classification
L01EX21
tepotinib
Level 1: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Level 2: ANTINEOPLASTIC AGENTS
Activity Summary
IC50 24 meas. best 8.93
Kd 2 meas. best 9.0
Target Activity Profile
| Target | Type | Best pChEMBL | Mean pChEMBL | Best (nM) | # Data |
|---|---|---|---|---|---|
| Hepatocyte growth factor receptor CHEMBL3717 | Kd | 9.0 | 9.0 | 1.0 | 1 |
| MHCC97H CHEMBL4296470 | IC50 | 8.93 | 8.39 | 1.2 | 3 |
| BaF3 CHEMBL614524 | IC50 | 8.82 | 7.19 | 1.5 | 11 |
| Hepatocyte growth factor receptor CHEMBL3717 | IC50 | 8.52 | 8.28 | 3.0 | 5 |
| Hs746T CHEMBL614579 | IC50 | 8.35 | 8.35 | 4.5 | 1 |
| SNU-16 CHEMBL613529 | IC50 | 6.44 | 6.44 | 363.0 | 1 |
| Ribosyldihydronicotinamide dehydrogenase [quinone] CHEMBL3959 | Kd | 6.06 | 6.06 | 875.0 | 1 |
| AGS CHEMBL613860 | IC50 | 5.84 | 5.84 | 1448.0 | 1 |
| HepG2 CHEMBL395 | IC50 | 5.44 | 5.44 | 3600.0 | 1 |
| L02 CHEMBL4296457 | IC50 | 4.97 | 4.97 | 10640.0 | 1 |
Pharmacokinetic Data
| Parameter | Value | Units | Species |
|---|---|---|---|
| CL | 60.0 | mL.min-1.kg-1 | Mus musculus |
| CL | 66.67 | mL.min-1.kg-1 | Mus musculus |
| CL | 78.33 | mL.min-1.kg-1 | Rattus norvegicus |
| CL | 12.17 | mL.min-1.kg-1 | Macaca fascicularis |
| CL | 55.0 | mL.min-1.kg-1 | Canis lupus familiaris |
| Cmax | 126.27 | nM | Mus musculus |
| Cmax | 133.99 | nM | Rattus norvegicus |
| Cmax | 112.67 | nM | Macaca fascicularis |
| Cmax | 45.47 | nM | Canis lupus familiaris |
| F | 34.0 | % | Mus musculus |
| F | 41.0 | % | Mus musculus |
| F | 55.0 | % | Rattus norvegicus |
| F | 25.0 | % | Macaca fascicularis |
| F | 22.0 | % | Canis lupus familiaris |
| Fu | 0.028 | - | Mus musculus |
| Fu | 0.041 | - | Rattus norvegicus |
| Fu | 0.052 | - | Macaca fascicularis |
| Fu | 0.064 | - | Canis lupus familiaris |
| Fu | 0.023 | - | Homo sapiens |
| T1/2 | 2.1 | hr | Mus musculus |
| T1/2 | 3.2 | hr | Rattus norvegicus |
| T1/2 | 10.0 | hr | Macaca fascicularis |
| T1/2 | 7.6 | hr | Canis lupus familiaris |
Activity Data Samples
Top measurements by pChEMBL value
Literature References
Data from ChEMBL 36 via Core Engine